Active Stocks
Thu Mar 28 2024 14:19:25
  1. Tata Steel share price
  2. 156.15 2.16%
  1. HDFC Bank share price
  2. 1,456.50 1.10%
  1. ITC share price
  2. 432.80 1.12%
  1. Power Grid Corporation Of India share price
  2. 278.05 2.58%
  1. State Bank Of India share price
  2. 758.60 3.34%
Business News/ Companies / Sanofi, Ascenta agree up to $398 mn cancer R&D deal
BackBack

Sanofi, Ascenta agree up to $398 mn cancer R&D deal

Sanofi, Ascenta agree up to $398 mn cancer R&D deal

Premium

Paris/London: Sanofi-Aventis boosted its early-stage pipeline on Friday with a deal worth up to $398 million for rights to experimental cancer compounds developed by US biotech firm Ascenta Therapeutics.

The most advanced compounds covered by the agreement, MI-773 and MI-519-64, are expected to enter preclinical development in 2010.

Ascenta is working on potential medicines that would be given by mouth to reactivate the tumour-suppressing function of the p53 gene. Ascenta itself in-licensed the compounds from the University of Michigan.

The US company will get an upfront payment and be eligible for milestone payments that could reach $398 million. It will also get tiered royalties on any eventual sales.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 04 Jun 2010, 11:56 AM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App

Chat with MintGenie